Cover Image

IL-6 and MYC collaborate in plasma cell tumor formation in mice

Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT). IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carrying a transgene, H2-Ld-IL6, that encodes human IL-6...

Full description

Saved in:
Bibliographic Details
Main Authors: Rutsch, Sebastian (Author) , Neppalli, Vishala T. (Author) , Shin, Dong-Mi (Author) , DuBois, Wendy (Author) , Morse, Herbert C., III (Author) , Goldschmidt, Hartmut (Author) , Janz, Siegfried (Author)
Format: Article (Journal)
Language:English
Published: [4 March 2010]
In: Blood
Year: 2010, Volume: 115, Issue: 9, Pages: 1746-1754
ISSN:1528-0020
DOI:10.1182/blood-2009-08-237941
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2009-08-237941
Get full text
Author Notes:Sebastian Rutsch, Vishala T. Neppalli, Dong-Mi Shin, Wendy DuBois, Herbert C., III Morse, Hartmut Goldschmidt, and Siegfried Janz
Description
Summary:Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT). IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carrying a transgene, H2-Ld-IL6, that encodes human IL-6 under control of the major histocompatibility complex H2-Ld promoter: strain C.H2-Ld-IL6. These mice are prone to PCT, but tumor development is incomplete with long latencies (∼ 40% PCT at 12 months of age). To generate a more robust mouse model of IL-6-dependent PCN, we intercrossed strain C.H2-Ld-IL6 with strains C.iMycEμ or C.iMycCα, 2 interrelated gene-insertion models of the chromosomal T(12;15) translocation causing deregulated expression of Myc in mouse PCT. Deregulation of MYC is also a prominent feature of human PCN. We found that double-transgenic C.H2-Ld-IL6/iMycEμ and C.H2-Ld-IL6/iMycCα mice develop PCT with full penetrance (100% tumor incidence) and short latencies (3-6 months). The mouse tumors mimic molecular hallmarks of their human tumor counterparts, including elevated IL-6/Stat3/Bcl-XL signaling. The newly developed mouse strains may provide a good preclinical research tool for the design and testing of new approaches to target IL-6 in treatment and prevention of human PCNs.
Item Description:Prepublished online as Blood First Edition paper, December 17, 2009
Gesehen am 12.01.2022
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2009-08-237941

Similar Items